Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score-matched analysis
- PMID: 35510082
- PMCID: PMC9036114
- DOI: 10.1016/j.prnil.2022.03.002
Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score-matched analysis
Abstract
Background: We investigated the association between moderate-to-severe prostatitis-like symptoms and the predictors of benign prostatic hyperplasia (BPH) progression.
Methods: Men who underwent health checkups were analyzed. We classified symptoms as "moderate to severe" if the pain score according to the National Institutes of Health-Chronic Prostatitis Symptoms Index was ≥8 and predictors of the progression of BPH were defined as having a prostate-specific antigen (PSA) ≥1.6 ng/mL, total prostate volume (TPV) ≥31 mL, international prostate symptom score (IPSS) ≥20, and maximal flow rate (Qmax) <10.6 mL/s. A total of 8368 patients formed the cohort for propensity score matching, including 445 men with moderate-to-severe prostatitis-like symptoms and 5390 men with no symptoms; ultimately, however, the propensity score of these groups matched at a 1:2 ratio.
Results: After propensity matching, the two groups were evenly distributed with respect to age, International Index of Erectile Function-5 score, metabolic syndrome, and testosterone. The percentage of participants with ≥1 predictor for the progression of BPH, a TPV of ≥31 cm3, PSA levels of ≥1.6 ng/mL, Qmax <10.6 mL/s, and IPSS ≥20 were all greater in men with moderate-to-severe prostatitis-like symptoms. There were significant differences in the percentage of participants with ≥1 predictor for the progression of BPH (30.6% vs. 58.0%; p < 0.001), Qmax <10.6 mL/s (3.9% vs. 7.0%, p = 0.023), and IPSS ≥20 (9.6% vs. 44.7%, p < 0.001).
Conclusion: Moderate-to-severe prostatitis-like symptoms are significantly and independently associated with predictors of BPH progression.
Keywords: Benign prostatic hyperplasia; Chronic prostatitis/chronic pelvic pain syndrome; International prostate symptom score; Maximal flow rate.
© 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V.
Conflict of interest statement
The authors have no potential or financial conflicts of interests to declare.
Similar articles
-
Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.Urol J. 2016 Jun 28;13(3):2717-26. Urol J. 2016. PMID: 27351328
-
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9. BJU Int. 2014. PMID: 24127818 Clinical Trial.
-
Relationship between erectile dysfunction and moderate to severe prostatitis-like symptoms in middle-aged men: a propensity score-matched analysis.Int Urol Nephrol. 2021 Nov;53(11):2261-2266. doi: 10.1007/s11255-021-02991-8. Epub 2021 Sep 21. Int Urol Nephrol. 2021. PMID: 34546557
-
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.BJU Int. 2019 Jul;124(1):27-34. doi: 10.1111/bju.14689. Epub 2019 Mar 11. BJU Int. 2019. PMID: 30681264
-
Prostatic Calculi: Do They Matter?Sex Med Rev. 2018 Jul;6(3):482-491. doi: 10.1016/j.sxmr.2017.10.003. Epub 2017 Nov 20. Sex Med Rev. 2018. PMID: 29157875 Review.
Cited by
-
Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study).Prostate Int. 2022 Dec;10(4):213-217. doi: 10.1016/j.prnil.2022.06.002. Epub 2022 Jun 20. Prostate Int. 2022. PMID: 36570649 Free PMC article.
-
Urological complications after COVID 19 vaccine according to age, sex and manufacturer.World J Urol. 2023 Aug;41(8):2255-2263. doi: 10.1007/s00345-023-04481-1. Epub 2023 Jul 3. World J Urol. 2023. PMID: 37400660
-
Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study.Prostate Int. 2024 Dec;12(4):195-200. doi: 10.1016/j.prnil.2024.06.003. Epub 2024 Jun 13. Prostate Int. 2024. PMID: 39735201 Free PMC article.
References
-
- Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97:3–6. - PubMed
-
- Crawford E.D., Wilson S.S., McConnell J.D., Slawin K.M., Lieber M.C., Smith J.A., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422–1427. - PubMed
-
- Tsunemori H., Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. Int J Urol. 2021 Nov;28(11):1086–1109. - PubMed
-
- Lee J.H., Lee S.W. Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. J Sex Med. 2015;12:697–704. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous